Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ: ARDX )

5.790 +0.130 (+2.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,515,028
Open 5.720
Bid (Size) 5.760 (1)
Ask (Size) 5.850 (20)
Prev. Close 5.660
Today's Range 5.640 - 5.885
52wk Range 4.320 - 9.830
Shares Outstanding 103,119,010
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
What Analysts Are Saying About Ardelyx Stock
Via Benzinga

Performance

YTD
+13.09%
+13.09%
1 Month
+12.21%
+12.21%
3 Month
+16.73%
+16.73%
6 Month
-3.34%
-3.34%
1 Year
-35.95%
-35.95%

More News

Read More
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock
Via Benzinga
Ardelyx Beats Q3 Sales Estimates, Shares Climb
Via Benzinga
Ardelyx's Earnings Outlook
Via Benzinga
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
From Ardelyx, Inc.
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi, LLP
Via Business Wire
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
ARDX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi LLP
Via GlobeNewswire
ARDX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
From Ardelyx, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.